Clinical trials: Standard Therapy
Moderate to Severe Psoriasis
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis
This is a single-center, open-label, pilot study. A total of 18 subjects will be enrolled in this 6 month study to evaluate whether the response to intralesional alefacept injections prior to the standard course of…
- Trial name
- NCT00678470
- Testing
- Intralesional Alefacept
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Acute Myelogenous Leukemia
Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
The goal of Part 1 of this clinical research study is to learn about the safety of the combination of plerixafor and clofarabine when given to patients with previously untreated AML who are at least 60 years old.
- Trial name
- NCT01160354
- Testing
- Plerixafor, Clofarabine
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatitis C
A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)
This study is being done to find out if the addition of boceprevir to standard of care (SOC) treatment with peginterferon alfa-2b (PegIFN-2b) + ribavirin (RBV) is effective for participants with chronic hepatitis C (CHC) genotype…
- Trial name
- NCT01756079
- Testing
- boceprevir, PegIFN-2b, RBV
- Volunteers
- 58 people
- Sponsor
- Merck Sharp & Dohme LLC
Medulloblastoma
Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
Participants enrolling on this study will receive standard of care chemotherapy for Wnt positive medulloblastoma without the radiation therapy or the weekly chemotherapy that is given during radiation therapy.
- Trial name
- NCT02212574
- Testing
- Lomustine, Vincristine, Cisplatin
- Where
- 16 sites in United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Emphysema
Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema
This study will look at outcomes between Endobronchial Coil Treatment and Control groups in patients with severe heterogeneous and or homogeneous emphysema.
- Trial name
- ELEVATE (NCT03360396)
- Testing
- Endobronchial Coils
- Where
- 19 sites in Austria, France and 4 more
- Volunteers
- 120 people
- Sponsor
- Boston Scientific Corporation
Alcohol Dependence
Baclofen as Add-On to Standard Treatment of Alcohol- Dependent Patients
This is a study of Baclofen as an add-on to standard treatment for alcohol-dependent patients.
- Trial name
- NCT01002105
- Testing
- Baclofen, Control group
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Sha'ar Menashe Mental Health Center
Neoplasm Metastasis
Stem Cell Transplantation for Metastatic Solid Tumors
The goal of this research study is to identify other types of cancer (malignant neoplasms) that may be treatable with stem cell transplantation (allogenic peripheral blood stem cell transplantation.
- Trial name
- NCT00001880
- Testing
- methotrexate, Cyclosporin
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Heart Failure
Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF
The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
- Trial name
- RELAX-AHF-ASIA (NCT02007720)
- Testing
- Serelaxin, Standard of CareTherapy
- Where
- 132 sites in China, India and 9 more
- Volunteers
- 876 people
- Sponsor
- Novartis Pharmaceuticals
Covid19
COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol
The overall objective of this study is to efficiently evaluate the clinical efficacy and safety of different investigational therapeutics among adults who have COVID-19 but are not yet sick enough to require hospitalization.
- Trial name
- NCT04662086
- Testing
- Acebilustat, Camostat
- Where
- 2 sites in United States
- Volunteers
- 122 people
- Sponsor
- Stanford University
Neovascular Age-related Macular Degeneration, Retinal Disease
A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration
This study is designed to investigate the safety and tolerability of GEM103 IVT injection + standard of care vs. sham + standard of care.
- Conditions
- Neovascular Age-related Macular Degeneration, Retinal Disease, Retinal Degeneration, Macular Degeneration
- Trial name
- NCT04684394
- Testing
- GEM103, Aflibercept
- Where
- 23 sites in United States
- Volunteers
- 50 people
- Sponsor
- Gemini Therapeutics, Inc.
Transitional Cell Carcinoma of Bladder, Superficial Bladder Cancer
Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
Hypothesis: In selected patients external hyperthermia will be used in combination with intravesical Mitomycin-C (MMC) to treat recurrent transitional cell carcinoma (TCC) of the bladder after local resection and standard…
- Trial name
- NCT00734994
- Testing
- Hyperthermia System, Mitomycin C
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mark Dewhirst
Wound of Knee, Wound of Hip
Study to Compare Negative Pressure Wound Therapy or Standard Dressings After Orthopedic Surgery
The aim of this study is to assess the prevention of incision healing complications in patients undergoing Total Knee Arthroscopy (TKA) and Total Hip Arthroscopy (THA) treated with either Single-Use Incisional NPWT (Negative…
- Trial name
- PICO (NCT02064270)
- Testing
- Single-Use Negative Pressure Wound Therapy, Standard postsurgical dressings
- Where
- United States
- Volunteers
- 526 people
- Sponsor
- University of Missouri-Columbia
Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
This randomized phase II trial studies how well hypofractionated radiation therapy (RT) works compared to standard RT in treating patients with ductal breast carcinoma in situ (DCIS) or early invasive breast cancer.
- Conditions
- Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v6, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT01266642
- Testing
- External Beam Radiation Therapy, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 7 sites in United States
- Volunteers
- 301 people
- Sponsor
- M.D. Anderson Cancer Center
Wilson Disease
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation…
- Trial name
- NCT03403205
- Testing
- ALXN1840, SoC Therapy
- Where
- 56 sites in United States, Australia and 20 more
- Volunteers
- 214 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Systemic Lupus Erythematosus
Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
This study will be conducted to assess the safety, tolerability, and immunogenicity of repeat doses of BOS161721 (20 milligrams [mg], 60 mg, and 120 mg) administered subcutaneously in adult participants with moderately to…
- Trial name
- NCT03371251
- Testing
- BOS161721
- Where
- 68 sites in United States, Argentina and 10 more
- Volunteers
- 143 people
- Sponsor
- Boston Pharmaceuticals
Malignant Solid Tumors, Lymphomas
tTF-NGR Phase I Study
In this phase I clinical trial cancer patients suffering from solid tumors or lymphomas, recurring after and/or refractory against standard treatment are treated intravenously (iv) with increasing doses of tTF-NGR(tTF= truncated…
- Trial name
- NCT02902237
- Testing
- tTF-NGR
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- University Hospital Muenster
Hepatitis C, Human Immunodeficiency Virus
Dutch Acute HCV in HIV Study (DAHHS)
Prospective open label proof of concept feasibility interventional clinical trial in which 60 acute HCV genotype 1 patients co-infected with HIV will receive 12 weeks of boceprevir in addition to Standard Of Care Peginterferon +…
- Trial name
- DAHHS (NCT01912495)
- Testing
- Boceprevir
- Where
- 9 sites in Netherlands
- Volunteers
- 65 people
- Sponsor
- Erasmus Medical Center
Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy
Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma
This is one randomized, double-blind, multi-center, placebo-controlled phase III study. The objective of this study is to compare the effectiveness and safety of JS001 combined with paclitaxel and cisplatin(TP regimen )with…
- Trial name
- JUPITER06 (NCT03829969)
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 514 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Psoriatic Arthritis
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
SPEED is a three arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests more aggressive early therapy in patients newly diagnosed with moderate to severe PsA.
- Trial name
- SPEED (NCT03739853)
- Testing
- Methotrexate, Sulfasalazine, Leflunomide
- Where
- United Kingdom
- Volunteers
- 192 people
- Sponsor
- University of Oxford
Gastrointestinal Neoplasms, Adenocarcinoma
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
The Phase 1b study is an open-label, multicenter dose escalation study designed to assess the safety, tolerability, immunogenicity and recommended phase 2 dose (RP2D) of IMU-131.
- Trial name
- NCT02795988
- Testing
- IMU-131, Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplatin and capecitabine.
- Where
- 22 sites in Georgia, India and 5 more
- Volunteers
- 64 people
- Sponsor
- Imugene Limited